Cytogenetics News and Research RSS Feed - Cytogenetics News and Research

Leica Biosystems, Mayo Clinic partner to develop next generation of cytogenetics imaging software

Leica Biosystems, Mayo Clinic partner to develop next generation of cytogenetics imaging software

Leica Biosystems and Mayo Clinic's Department of Laboratory Medicine and Pathology announced today a collaboration to develop the next generation of cytogenetics imaging software. The new tool will optimize software workflow and improve the overall user experience for cytogenetics imaging technicians. [More]
Actimab-A extends overall survival, reduces bone marrow blasts in older AML patients

Actimab-A extends overall survival, reduces bone marrow blasts in older AML patients

Interim data from an ongoing Phase I/II trial of Actimab-A, an innovative targeted payload immunotherapy, demonstrated a number of positive findings, including extension of overall survival and significant reductions in bone marrow blasts in older patients with newly diagnosed Acute Myeloid Leukemia (AML). [More]
Scientists identify new biomarker for diagnosing cause of thyroid cancer

Scientists identify new biomarker for diagnosing cause of thyroid cancer

The expression of the protein CLIP2 provides information on whether a papillary thyroid carcinoma was induced by radiation or had a sporadic origin. With this discovery, scientists from the Helmholtz Zentrum München have identified a new biomarker for the diagnosis of the cancer cause. [More]
Daiichi Sankyo, Ambit Biosciences enter into definitive merger agreement

Daiichi Sankyo, Ambit Biosciences enter into definitive merger agreement

Daiichi Sankyo Company, Ltd. (hereinafter Daiichi Sankyo) and Ambit Biosciences, jointly announced today that they have entered into a definitive merger agreement under which Daiichi Sankyo will acquire all of the outstanding common stock of Ambit Biosciences for $15 per share in cash through a tender offer followed by a merger with a subsidiary of Daiichi Sankyo, or approximately $315 million on a fully diluted basis. [More]
OGT to highlight NGS and FISH methods for tumour screening at BSGM 2014

OGT to highlight NGS and FISH methods for tumour screening at BSGM 2014

Oxford Gene Technology, The Molecular Genetics Company, is inviting attendees of the British Society for Genetic Medicine annual conference to its seminar entitled ‘Approaches to tumour screening and therapy stratification: case studies in Non-Small Cell Lung Cancer’ on Monday 22nd September, 13.10-13.50, room 2N. [More]
CAP awards accreditation to The Children's Hospital of Philadelphia Pathology & Laboratory Medicine

CAP awards accreditation to The Children's Hospital of Philadelphia Pathology & Laboratory Medicine

The Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to The Children's Hospital of Philadelphia Pathology & Laboratory Medicine, Philadelphia, Pennsylvania based on results of a recent on-site inspection as part of the CAP's Accreditation Programs. [More]
NeoGenomics launches 23 NGS-based NeoTYPE Cancer Profiles

NeoGenomics launches 23 NGS-based NeoTYPE Cancer Profiles

NeoGenomics, Inc., a leading provider of cancer-focused genetic and molecular testing services, announced today it has launched 23 new and innovative NeoTYPE Cancer Profiles based on next-generation sequencing (NGS). [More]
Greenwood Genetic and Clemson receive first round of fund from SRHC

Greenwood Genetic and Clemson receive first round of fund from SRHC

Seven research projects from Greenwood Genetic Center and Clemson University faculty were selected to receive the first round of funding provided by Self Regional Healthcare (SRHC). [More]
Affymetrix, BioDiscovery launch new analysis software for cancer research

Affymetrix, BioDiscovery launch new analysis software for cancer research

Affymetrix and BioDiscovery, Inc. today announced the launch of a new analysis software, Nexus Copy Number for Affymetrix, which is specifically for data generated by Affymetrix' genetic analysis platforms in cancer research, including CytoScan Cytogenetics Suite and OncoScan FFPE Assay Kit. [More]
Scientists reproduce chromosomal modifications in human cells that cause certain cancer

Scientists reproduce chromosomal modifications in human cells that cause certain cancer

Scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) and the Centro Nacional de Investigaciones Oncol-gicas (CNIO) have succeeded in reproducing, in human cells, the chromosomal translocations that cause two types of cancer: acute myeloid leukemia and Ewing's sarcoma. [More]
Researchers reproduce tumor chromosomal translocations in human cells

Researchers reproduce tumor chromosomal translocations in human cells

Scientists from the Spanish National Cancer Research Centre and the Spanish National Cardiovascular Research Centre have been able to reproduce, for the first time in human cells, chromosomal translocations associated with two types of cancer: acute myeloid leukaemia and Ewing's sarcoma. [More]
Transgenomic signs license with Dana-Farber to develop multiplexed ICE COLD-PCR technology

Transgenomic signs license with Dana-Farber to develop multiplexed ICE COLD-PCR technology

Transgenomic, Inc., a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic tests and clinical and research services, today announced that it has signed a license with the Dana-Farber Cancer Institute for worldwide rights to develop and commercialize multiplexed versions of its ICE COLD-PCRTM technology (MX ICE COLD-PCR). [More]
NeoGenomics selects Aurora as primary partner for molecular testing

NeoGenomics selects Aurora as primary partner for molecular testing

NeoGenomics, Inc., a leading provider of cancer-focused genetic and molecular testing services, announced today that it has been selected by Aurora Diagnostics to be its primary partner for molecular testing at each of Aurora's 19 specialized anatomic pathology laboratories in the United States. [More]
NeoGenomics' revenue up 16.1% in first quarter 2014

NeoGenomics' revenue up 16.1% in first quarter 2014

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services today reported its results for the first quarter of 2014. [More]
OGT releases new application note detailing performance of two DNA labelling kits

OGT releases new application note detailing performance of two DNA labelling kits

Oxford Gene Technology, The Molecular Genetics Company, has released a new application note detailing the technical evaluation of two DNA labelling kits, where OGT’s CytoSure Genomic DNA Labelling Kits were found to be quicker and more accurate than a leading alternative. [More]
Irvine Scientific announces launch of BalanCD MDCK cell culture medium

Irvine Scientific announces launch of BalanCD MDCK cell culture medium

Irvine Scientific is pleased to announce the launch of its BalanCD MDCK cell culture medium, a next generation cell culture product responding to today's requirements for media used in cell-based vaccine manufacturing. This new flagship product expands Irvine Scientific's current BalanCD product portfolio of animal component-free and chemically-defined media with the addition of a new purpose-built product. [More]
Harvard Medical School researcher receives 2014 Richard King Trainee Award

Harvard Medical School researcher receives 2014 Richard King Trainee Award

​Huma Q. Rana, MD of Harvard Medical School's Dana Farber Cancer Institute is the recipient of the 2014 Richard King Trainee Award. This award was instituted five years ago by the ACMG Foundation for Genetic and Genomic Medicine to encourage ABMG or genetic counseling trainees in their careers and to foster the publication of the highest quality research in ACMG's peer-reviewed journal, Genetics in Medicine (GIM). [More]
Transgenomic to provide genetic testing services for Raptor’s clinical trial

Transgenomic to provide genetic testing services for Raptor’s clinical trial

Transgenomic, Inc., a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, today announced an agreement with Raptor Pharmaceuticals Inc. to provide genetic testing services for Raptor's clinical trial (RP103-MITO-001) evaluating RP103 as a potential treatment for Leigh syndrome and other inherited mitochondrial disorders. [More]
Oxford Gene Technology releases latest version of CytoSure Interpret Software

Oxford Gene Technology releases latest version of CytoSure Interpret Software

Oxford Gene Technology, The Molecular Genetics Company, is pleased to announce the latest version (4.5.3) of its class-leading CytoSure Interpret Software. [More]
Oxford Gene Technology announces acquisition of Cytocell

Oxford Gene Technology announces acquisition of Cytocell

Oxford Gene Technology, a provider of innovative genetics research solutions, today announced the acquisition of Cambridge-based Cytocell Limited, a leading provider of DNA technology for the detection of gene rearrangements related to inherited genetic disease and cancer. [More]